Health authorities are growing concerned about the limited effectiveness of antibiotics to treat the common sexually transmitted infection.
Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results